Yale Journal of Biology and Medicine Interview with AIM-HI-Invested Company Co-Founder
We are doing a randomized multi-center international clinical trial with a target population of hepatitis B virus-associated hepatocellular carcinoma. In order to develop PHY906 as a drug, we formed a company called Yiviva, in which Yale is a co-founder…
Read more: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309656/
